PUBLIC COMPANY
save$ARTVArtiva Biotherapeutics, Inc.
$ARTVSan Diego, CA, USupdated 21d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Preclinical1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- phase2AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- phase1AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
- phase2A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Insider activity
source: SEC Form 4routine RSU / option mechanics (1)
- Mar 10, 26grantHuston Thad Allen · Chief Financial Officer220,000 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that